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ABSTRACT
Objectives: The purpose of this study was to retrospectively analyze maternal and neonatal outcomes in pregnant women 
with mild gestational diabetes mellitus at 39 weeks compared to 40 weeks.
Material and methods: Clinical data of 372 cases of mild gestational diabetes mellitus form First Affiliated Hospital of Sun 
Yat-sen University were analyzed retrospectively. There were 108 mild GDM patients that delivered at 40–40+6 weeks in our 
research group, and 264 patients that delivered in 39–39+6 weeks in the control group. Neonatal and maternal outcomes 
were compared between the two groups.
Results: There was no difference between the two groups in the rate of cesarean section (42.6% vs. 45.5%, p = 0.614). The 
incidence of large for gestational age between the two groups was also not different (11.1% vs. 10.6%, p = 0.887). The 
rate of postpartum hemorrhage and shoulder dystocia of the two groups was not different either (p > 0.05). There was 
no significant difference in the incidence of fetal distress, neonatal asphyxia, neonatal pathological jaundice, neonatal 
hypoglycemia, and neonatal respiratory distress syndrome in the two groups (p > 0.05).
Conclusions: There were no significant differences in adverse pregnancy outcomes and neonatal outcomes in women 
with mild gestational diabetes between deliveries at 39 and 40 weeks. 
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INTRODUCTION
Gestational diabetes mellitus (GDM) is one of the most 
common complications in pregnancy. It is reported that the 
incidence of GDM varies from l% to 20% [1–4]. Although 
the effects of GDM on mother and fetus have been widely 
recognized, there are still many problems to be solved. Previ-
ous studies have shown that elective induction at 38 com-
plete weeks reduces newborn weight and related complica-
tions [5]. American Diabetes Association (ADA) supported 
this in 2003 by pointing out that prolonging gestation past 
38 weeks increased the risk of fetal macrosomia without 
reducing cesarean rates, so delivery during the 38th week 
shall be preferred [6]. In recent years however, it has been 
argued that the evidence of inducing deliveries at 38 weeks 
to prevent the occurrence of macrosomia and other GDM 
complications is insufficient [7, 8]. Despite more and more 
understanding of GDM and the application of new standard 
GDM criteria released by International Association of Diabetes 
and Pregnancy Study Groups (IADPSG), the incidence of GDM 
has been rising significantly. Thus, the management of GDM 
patients may seem controversial. What is the appropriate tim-
ing to delivery then? It is widely agreed that a pregnant GDM 
woman should deliver before 40 weeks of gestation because 
of an increased risk of stillbirth. On the other hand however, 
based on conflicting findings in literature and our practice, 
such risk-increase seems not to apply in cases of mild GDM 
that is early well-controlled and uncomplicated. Therefore, it 
would be conclusive to find out the best delivery time in mild 
GDM cases. Therefore, the purpose of this study was to com-
pare maternal and neonatal outcomes at 39 versus 40 weeks 
of mild GDM, and to provide additional clinical evidence of 
optimal delivery timing for mild GDM.
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MATERIAL AND METHODS
Data was collected from patients in obstetrics depart-
ment of First Affiliated Hospital of Sun Yat-Sen University 
between March 2014 and August 2015. The data included: 
demographics, complications, delivery information as well 
as maternal and neonatal outcomes. The inclusion crite-
ria included: (1) single pregnancy, vertex; (2) delivery by 
elective or emergency caesarean section and by spon-
taneous labor or induction at ≥ 39 weeks; (3) failed oral 
glucose tolerance test (OGTT) during 24–28 weeks [9]; 
(4) satisfactory glycemia control; (5) no complications. Ex-
clusion criteria included: multiple pregnancy; delivery 
at < 39 weeks; pregnancy associated with other diseases 
or other obstetric complications such as intrahepatic chol-
estasis syndrome during pregnancy or severe infection; 
pre-gestational diabetes mellitus; poor glycemic control; 
GDM requiring medication for control. Patient information 
was collected from electronic documents and included 
age, body mass index (BMI), parity, weight gain, OGTT 
value, mode of delivery, postpartum hemorrhage and 
other complications, perineal laceration, shoulder dysto-
cia, neonatal birth weight, fetal distress, neonatal asphyxia, 
respiratory distress syndrome. 
Outcomes were categorized into maternal outcomes 
and neonatal outcomes. Maternal outcomes include preg-
nancy induced hypertension, postpartum hemorrhage, and 
perineal laceration. Neonatal outcomes include shoulder 
dystocia, macrosomia, large for gestational age (LGA), small 
for gestational age (SGA), birth injury, neonatal death, neo-
natal hypoglycemia, fetal distress, neonatal asphyxia.
In this study the criteria used to diagnose GDM were 
those of IADPSG [9]. The fasting blood glucose test (FBG) 
was performed at the very first prenatal examination to 
exclude pre-gestational diabetes (FBG ≥ 7.00 mmol/L). All 
patients in this study underwent a 2-hour 75 g oral glucose 
tolerance test at 24–28 gestation weeks with readings at 
0 h, 1 h and 2 hours. GDM was diagnosed when any one of 
the 75 g OGTT conditions was met: FBG ≥ 5.1 [mmol/L]; 1 h 
after load ≥ 10.0 [mmol/L]; 2 h after load ≥ 8.5 [mmol/L]. All 
patients were taught to control diet, exercise and monitor 
blood glucose. Mild GDM patients, to control their blood 
glucose level, needed diet control and exercise therapy 
only. Satisfaction with blood glucose levels was meas-
ured in Patients with fasting blood glucose < 5.3 [mmol/L] 
and postprandial glucose at 1 hour < 7.8 [mmol/L] or at 
2 hours < 6.7 [mmol/L] after eating were considered to 
have satisfactory blood glucose levels and did not require 
medication. All clinical investigations were conducted in 
accordance with the guidelines of the Declaration of Hel-
sinki and were approved by the Hospital Ethics Committee 
[No. 2014(93)]. Informed consent was obtained from all 
participating parties.
Statistical methods
Maternal and delivery data was described by percentages 
and mean ± SD. Categorical variables were compared using 
Chi-square test or Fisher’s exact test while continuous varia- 
bles using unpaired Student’s t test. Statistical analysis was 
carried out using IBM SPSS statistical package version 19.0. The 
p value < 0.05 was considered as statistically significant. 
RESULTS
During the studied period there were 5145 cases of 
deliveries in our hospital, of which 967 cases (18.8%) were 
diagnosed as gestational diabetes mellitus. There was a total 
of 435 of GDM deliveries beyond 39 weeks but 63 cases were 
excluded from the study, of which 13 due to pre-gestational 
diabetes mellitus, 27 due to unsatisfactory blood glucose 
control, 16 due to incomplete records and 7 due to insuf-
ficient monitoring of blood glucose. Consequently, there 
were 372 cases that met the study criteria: 264 deliveries 
at 39–39+6 weeks and 108 deliveries beyond 40 complete 
gestation weeks. Maternal age ranged from 18 to 44 years, 
with an average of 31.6 ± 3.9 years.
The weight gain during pregnancy in the study group 
was significantly higher than that in the control group 
(13.20 ± 4.54 [kg] vs. 11.53 ± 3.72 [kg], p < 0.001). In the study 
group, the proportion of multiparas was significantly lower 
than that of the control group (17.6% vs. 31.1%, p = 0.008). 
There was no significant difference in mode of conception, 
spontaneous abortion rate, OGTT value at 0 h (FBG) or at 
1 h, nor in glycosylated hemoglobin level (HbA1c) (p > 0.05) 
between the two groups. The data is summarized in Table 1.
Also, the two groups showed no significant difference 
in cesarean section rate, postpartum hemorrhage, shoulder 
dystocia or cervical laceration (p > 0.05). We recorded a sec-
ond degree perineal laceration in only one case and none of 
severe damage (3rd or 4th degree). The pregnancy outcomes 
and complications are presented in Table 2.
Similarly, there was no significant difference in other ad-
verse events such as the rate of macrosomia, fetal distress, 
neonatal asphyxia, LGA, neonatal pathological jaundice, neo-
natal hypoglycemia or neonatal respiratory distress syndrome 
(RDS) (p > 0.05). There was no significant difference between 
the two groups in SGA either, but the proportion of SGA in the 
study group was lower than that in the control group (5.6% 
vs. 11.7%, p = 0.070). There was no intrauterine fetal death re-
corded. The average neonatal weight of the study group was 
slightly higher than that of the control group (3.33 ± 0.35 [kg] 
vs. 3.25 ± 0.38 [kg], p = 0.042). The neonatal outcomes in the 
two groups are summarized in Table 3.
DISCUSSION
The diagnostic criteria for gestational diabetes mel-
litus vary across countries and regions. Consequently, the 
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incidence of GDM is different and may vary even within the 
same country, as standards are not uniform. The incidence 
of GDM in China has reached 17.5% according to data from 
a multicenter clinical trial in China [10]. Although there is 
now a greater understanding of GDM and most cases are 
well managed having a satisfactory glycemic control, the 
GDM complications and fetal macrosomia are still on a rise 
significantly [11]. Maternal high blood glucose crosses pla-
centa and circulates in the fetus stimulating fetal insulin se-
cretion. That leads to increased anabolism and deposition of 
fat and glycogen in the fetal tissue, hence fetal macrosomia. 
Such newborns have higher risk of shoulder dystocia, bra- 
Table 1. Basic data of the two groups
Items Research group Control group X2 P value
N 108 264
Age (years) 30.60 ± 3.49 32.00 ± 3.93 3.224* 0.001
≥ 35 years 17 (15.7%) 63 (23.9%) 2.996 0.083
Mean abortions 0.51 ± 0.80 0.62 ± 0.93 1.060* 0.290
Conception 
Natural 99 (91.7%) 234 (88.6%) 0.750 0.386
Artificial 9 (8.3%) 30 (11.4%)
BMI before delivery
18.9–24.9 [kg/m2] 32 (29.6%) 104 (39.4%)
25.0–29.9 [kg/m2] 56 (51.9%) 137 (51.9%)
≥ 30 [kg/m2] 20 (18.5%) 23 (8.7%) 8.375 0.015
Weight gain [kg] 13.20 ± 4.54 11.53 ± 3.72 –3.668 < 0.001
Primipara 89 (82.4%) 182 (68.9%) 7.029 0.008
Multipara 19 (17.6%) 82 (31.1%)
Mean OGTT reading [mmol/L]
At 0 h (FBG) 4.72 ± 0.46 4.74 ± 0.57 0.198 0.843
At 1 h 9.72 ± 1.35 9.76 ± 1.50 0.248 0.804
At 2 h 8.59 ± 1.18 8.95 ± 1.25 2.568 0.011
HbA1c (%) 5.37 ± 0.50 5.41 ± 0.38 0.794 0.427
# of cases with abnormal values at any of the 3 OGTT readings
Any 1 out of 3 65 (60.2%) 140 (53.0%)
Any 2 out of 3 36 (33.3%) 95 (36.0%)
All 3 readings abnormal 7 (6.5%) 29 (11.0%) 2.471 0.291
*Student’s t test; BMI — body mass index; OGTT — oral glucose tolerance test; FPG — fasting plasma glucose; HbA1c — hemoglobin A1c
Table 2. Outcomes and complications of the two groups
Items Research group Control group X2 P value
N 108 264
Spontaneous labor 53 (49.1%) 129 (48.9%)
Forceps 9 (8.3%) 15 (5.7%) 0.977 0.614
Cesarean section 46 (42.6%) 120 (45.5%)
Pregnancy hypertension 9 (8.3%) 20 (7.6%) 0.061 0.805
Postpartum hemorrhage 15 (13.9%) 35 (13.3%) 0.026 0.871
Vaginal injury 3 (2.8%) 7 (2.7%) – 1.000*
Cervical laceration 8 (7.4%) 13 (4.9%) 0.887 0.346
Shoulder dystocia 3 (2.8%) 4 (1.5%) – 0.419*
*Fisher’s exact test
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chial plexus injury and neonatal asphyxia. Therefore, previ-
ous studies and guidelines have recommended the use of 
elective delivery method within 38 weeks to minimize macro- 
somia and associated complications. In 2008 National Institute 
for Health & Clinical Excellence (NICE) in UK recommended 
that a GDM fetus, if normal, could be delivered by induction 
at 38 weeks of gestation or by elective cesarean section [12]. 
However, such strategy has been controversial while prac-
tice showed it was far from easy to determine the optimal 
time for delivery. It is generally agreed that a GDM pregnant 
women should deliver before 40 weeks. In recent years, 
the discussion about the appropriate timing of delivery of 
GDM has been focused on the necessity to intervene either 
before or after 40 weeks of gestation, where in case of the 
latter, the risk of fetal distress and fetal death may increase. 
Eman et al. thought that the recommendations on optimal 
time window for delivery in GDM are not precise enough 
and have weak foundations. Simply, there is no evidence 
that electively induced labor is any better than spontaneous 
natural labor past 40 weeks. The authors further suggested 
that in GDM cases with ideal blood glucose control and no 
complications it is not necessary at all to deliver at 40 weeks 
the latest [4]. Mpondo et al. [7] suggested that despite the 
common belief that GDM pregnancy should be delivered 
at term, there was no adequate evidence for ideal timing 
and mode of delivery in GDM cases based on retrospective 
analysis. Sutton et al. [13] have analyzed retrospectively 
a total of 679 cases with mild GDM. The results showed 
that GDM deliveries before 40 weeks did not increase the 
cesarean section rate. In contrast, the incidence of Cesar-
ean section of GDM at 40 weeks increased, but only in the 
induced group when compared to expected pregnancy 
at 40 weeks. Cesarean section rate increased significantly 
delivering beyond 40 weeks. In their comparison however 
the authors did not take into consideration the pregnancy 
outcomes nor the neonatal outcomes. Witkop et al. [14] 
have reviewed a few studies and found that in case of GDM 
pregnancy with good glycemic control, the incidence of 
macrosomia and associated complications can be reduced 
if management is active (induction at term) rather than ex-
pectant. In 2015 NICE brought to the attention that there 
was no convincing evidence that GDM pregnancy with ap-
propriately managed glycemia has still an increased risk of 
a stillbirth but there was sufficient evidence to recommend 
induction of labor prior to 40 weeks of gestation to reduce 
the risk of shoulder dystocia [15].
The elective induction of labor is considered to be rou-
tine management of pregnant women with GDM in order to 
reduce the incidence of macrosomia and related complica-
tions. However, selective induction of labor was associated 
with prolonged labor, fetal distress, increased cesarean sec-
tion rate, and shoulder dystocia [16–19]. Witkop et al. have 
compared elective induction with expectant management. 
The results showed that elective induction can significantly 
reduce the rate of LGA and shoulder dystocia, but due to 
immature cervical ripening of early induction, the failure 
rate increased. The elective induction at less than 38 weeks 
has a higher rate of vaginal delivery failure, which results 
with transit to cesarean section anyways [14]. The results 
of our study show that there is no difference in the rate of 
cesarean section, the rate of difficult birth, the incidence 
of macrosomia or the incidence of neonatal hypoglycemia 
whether delivered before or after 40 weeks. Such findings 
may be due to well-implemented strict procedures at our 
hospital; all study participants had a very well controlled 
glycemia. Another reason may be on account of the use 
of the GDM criteria from IADPSG recently implemented 
at our center, which are more inclusive (not satisfying any 
Table 3. Neonatal outcomes of the two groups
Items Research group Control group X2 P value
N 108 264
Weight [kg] 3.33 ± 0.35 3.25 ± 0.38 –1.976* 0.049
Macrosomia 4 (3.7%) 11 (4.2%) – 1.000#
Fetal distress 35 (32.4%) 77 (29.2%) 0.383 0.536
Neonatal asphyxia 1 (0.9%) 8 (3.0%) – 0.457#
Male 56 (51.9%) 138 (52.3%) 0.005 0.941
LGA 12 (11.1%) 28 (10.6%) 0.020 0.887
SGA 6 (5.6%) 31 (11.7%) 3.275 0.070
Jaundice 23 (21.3%) 40 (15.2%) 2.057 0.151
Hypoglycemia 6 (5.6%) 21 (8.0%) 0.655 0.418
RDS 2 (1.9%) 3 (1.1%) – 0.630#
*Student’s t test, #Fisher’s exact test; LGA — large for gestational age; SGA — small for gestational age; RDS — neonatal respiratory distress syndrome
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of the 3 OGTT readings classifies as GDM). This resulted in 
some of our cases to be classified as GDM, although they 
were not GDM under criteria previously used by us. We had 
a total of 15 cases of macrosomia in our study. The rate of 
macrosomia was not significantly differences between the 
two groups. The incidence of macrosomia was low because 
of strict management in this study including health educa-
tion, diet control, exercise and blood glucose control. The 
effect was that none of the study participants needed insulin 
or oral medication. Such education was possible thanks to 
GDM day clinics that in China play an important role in the 
management of GDM pregnancies. Interestingly, this study 
showed that the percentage of SGA in 40 weeks of pregnan-
cy was lower than that in the control group (5.6% vs. 11.7%, 
p = 0.070), which is in line with intuition due to extra week 
of growth. We hypothesized that a well-managed strict gly-
cemic control was the major factor for the overall SGA rate 
while we recorded no case of maternal hypoglycemia. Also, 
it may be that the strict GDM criteria of IADPSG that classify 
a previously normal pregnancy as abnormal glycemia preg-
nancy cause inclusion to the study and the management 
of GDM. When it comes to the neonatal weight, although 
the average weight in the 40 weeks group was significantly 
higher than that in the 39 weeks group, the absolute differ-
ence was very small.
The difference between the present study and other 
studies was that patients who participated in this study were 
mild GDM cases where mild is defined as that with good 
glycemic control due to exercise and adequate diet only. 
This way we minimize the interference factor of different 
diabetes types. The mean weight gain during pregnancy of 
the study group was bigger than that of the control group 
(13.20 ± 4.54 vs. 11.53 ± 3.72 [kg], p < 0.001).
There was no difference between the two groups in 
shoulder dystocia. Interestingly, all shoulder dystocias oc-
curred in non-macrosomic cases. Consequently, fetal weight 
less than 4000 [g] does not completely exclude the risk of 
shoulder dystocia. Fetal fat distribution and delivery mecha-
nisms may be important risk factors for shoulder dystocia. 
There was no fetal death in this study, which may be 
related to the strict blood glucose control, monitoring and 
management during pregnancy. This suggests that a strict 
control of blood glucose is essential to improve neonatal 
outcome.
CONCLUSIONS
It has been shown that it is not necessary to choose cesar-
ean section to prevent macrosomia and related complications 
for patients with mild GDM. The results of this study showed 
that mild GDM pregnancies delivered beyond 39 weeks did 
not increase the adverse maternal and neonatal outcomes 
compared to pregnancy resolution at 39 weeks. Since this 
study is a retrospective study, it has some inherent limits. More 
randomized controlled studies are needed to examine the 
risks and benefits of a delayed delivery.
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